Lexicon Pharmaceuticals, Inc.
LXRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 2,481.5% | 766.2% | -53.4% | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | 98% | -4,798% | -37,681.3% | -18,371.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -592.9% | -14,099.3% | -71,966.2% | -29,126.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -644.8% | -14,710.9% | -73,341% | -29,449% |
| EPS Diluted | -0.63 | -0.8 | -0.62 | -0.61 |
| % Growth | 21.3% | -29% | -1.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |